The continued advance of vaccine adjuvants – ‘we can work it out’ DOI Creative Commons

Derek T. O’Hagan,

Rushit N. Lodaya, Giuseppe Lofano

et al.

Seminars in Immunology, Journal Year: 2020, Volume and Issue: 50, P. 101426 - 101426

Published: Aug. 1, 2020

In the last decade there have been some significant advances in vaccine adjuvants, particularly relation to their inclusion licensed products. This was proceeded by several decades which such were very scarce, or entirely absent, but novel adjuvants now included products, including US. These relied upon key technological insights that emerged this time period, finally allowed an depth understanding of how work. include developments systems biology approaches allow hypotheses first advanced pre-clinical studies be critically evaluated human studies. review highlights these recent advances, both themselves, also technologies enabled successes. Moreover, we appraise what will come next, terms new adjuvant molecules, and needed them succeed. We confidently predict additional emerge coming years reach approval components might differ significantly from those are currently used. Gradually, natural products originally used build since they readily available at initial development, replaced synthetic biosynthetic materials, with more appealing attributes, reliable robust supply, along reduced heterogeneity. The advance is timely, given need create vaccines deal COVID-19 pandemic. Although, must ensure rigorous safety evaluations current not ‘short-changed’ push for meet global challenge as quickly possible, jeopardize achieved, pushing less established too quickly, if data does fully support it.

Language: Английский

Cancer vaccines: Building a bridge over troubled waters DOI Creative Commons

MacLean C. Sellars,

Catherine J. Wu, Edward F. Fritsch

et al.

Cell, Journal Year: 2022, Volume and Issue: 185(15), P. 2770 - 2788

Published: July 1, 2022

Language: Английский

Citations

197
Engineered Nanoparticles for Cancer Vaccination and Immunotherapy DOI

Marisa Aikins,

Cheng Xu, James J. Moon

et al.

Accounts of Chemical Research, Journal Year: 2020, Volume and Issue: 53(10), P. 2094 - 2105

Published: Oct. 5, 2020

ConspectusThe immune system has evolved over time to protect the host from foreign microorganisms. Activation of is predicated on a distinction between self and nonself. Unfortunately, cancer characterized by genetic alterations in host's cells, leading uncontrolled cellular proliferation evasion surveillance. Cancer immunotherapy aims educate not only recognize but also attack kill mutated cells. While checkpoint blockers have been proven be effective against multiple types advanced cancer, overall patient response rate still remains below 30%. Therefore, there an urgent need improve current immunotherapies. In this Account, we present overview our recent progress nanoparticle-based strategies for improving vaccines We other complementary give well-rounded snapshot field combination immunotherapy. The versatility tunability nanoparticles make them promising platforms addressing individual challenges posed various cancers. For example, can deliver cargo materials specific such as delivered antigen-presenting cells strong activation. Nanoparticles allow stimuli-responsive delivery therapeutics thus forming basis Here, focus nanoparticle engineered tumor antigens, whole chemotherapeutic or phototherapeutic agents manner effectively safely trigger each work, discuss platform developed, synthesis chemistry, vivo applications. Nanovaccines offer unique codelivery personalized neoantigens adjuvants elicitation robust responses aggressive tumors. either delivering cell lysate formed may increase repertoire antigens targets while exploiting immunogenic death prime antitumor responses. how antigen- cell-based approaches open door vaccination On hand, chemotherapy, phototherapy, radiotherapy are more standardized therapies, promote their ability initiate T activation efficacy with minimal toxicity. Finally, building immunotherapy, should set ultimate goal clinical translation efficacy. will regulatory, analytical, manufacturing hurdles that addressed expedite nanomedicine-based

Language: Английский

Citations

181
Transdermal vaccination via 3D-printed microneedles induces potent humoral and cellular immunity DOI Creative Commons

Cassie L. Caudill,

Jillian L. Perry,

Kimon Iliadis

et al.

Proceedings of the National Academy of Sciences, Journal Year: 2021, Volume and Issue: 118(39)

Published: Sept. 22, 2021

Vaccination is an essential public health measure for infectious disease prevention. The exposure of the immune system to vaccine formulations with appropriate kinetics critical inducing protective immunity. In this work, faceted microneedle arrays were designed and fabricated utilizing a three-dimensional (3D)-printing technique called continuous liquid interface production (CLIP). design resulted in increased surface area as compared smooth square pyramidal design, ultimately leading enhanced coating model components (ovalbumin CpG). Utilizing fluorescent tags live-animal imaging, we evaluated vivo cargo retention bioavailability mice function route delivery. Compared subcutaneous bolus injection soluble components, transdermal delivery not only skin but also improved cell activation draining lymph nodes. Furthermore, induced potent humoral response, higher total IgG (Immunoglobulin G) more balanced IgG1/IgG2a repertoire achieved dose sparing. it elicited T responses characterized by functional cytotoxic CD8+ cells CD4+ secreting Th1 (T helper type 1)-cytokines. Taken together, CLIP 3D-printed microneedles coated provide useful platform noninvasive, self-applicable vaccination.

Language: Английский

Citations

146
Vaccine delivery systems toward lymph nodes DOI

Yingyue Ding,

Zhaoting Li, Ana Jaklenec

et al.

Advanced Drug Delivery Reviews, Journal Year: 2021, Volume and Issue: 179, P. 113914 - 113914

Published: Aug. 4, 2021

Language: Английский

Citations

123
Toll-like receptor (TLR) agonists as a driving force behind next-generation vaccine adjuvants and cancer therapeutics DOI Creative Commons
Arshpreet Kaur, Jeremy Baldwin, Deshkanwar Brar

et al.

Current Opinion in Chemical Biology, Journal Year: 2022, Volume and Issue: 70, P. 102172 - 102172

Published: July 1, 2022

Language: Английский

Citations

109
Biomaterial-assisted biotherapy: A brief review of biomaterials used in drug delivery, vaccine development, gene therapy, and stem cell therapy DOI Creative Commons
Xuejiao Han, Aqu Alu, Hongmei Liu

et al.

Bioactive Materials, Journal Year: 2022, Volume and Issue: 17, P. 29 - 48

Published: Jan. 19, 2022

Biotherapy has recently become a hotspot research topic with encouraging prospects in various fields due to wide range of treatments applications, as demonstrated preclinical and clinical studies. However, the broad applications biotherapy have been limited by critical challenges, including lack safe efficient delivery systems serious side effects. Due unique potentials biomaterials, such good biocompatibility bioactive properties, biomaterial-assisted be an attractive strategy. The biomaterial-based possess sufficient packaging capacity versatile functions, enabling sustained localized release drugs at target sites. Furthermore, biomaterials can provide niche specific extracellular conditions for proliferation, differentiation, attachment, migration stem cells, leading tissue regeneration. In this review, state-of-the-art studies on biotherapy, drug delivery, vaccine development, gene therapy, cell summarized. challenges outlook biotherapies also discussed.

Language: Английский

Citations

105
A Minimalist Binary Vaccine Carrier for Personalized Postoperative Cancer Vaccine Therapy DOI
Jiayu Zhao,

Yudi Xu,

Sheng Ma

et al.

Advanced Materials, Journal Year: 2022, Volume and Issue: 34(10)

Published: Jan. 5, 2022

In recent years, significant evolutions have been made in applying nanotechnologies for prophylactic and therapeutic cancer vaccine design. However, the clinical translation of nanovaccines is still limited owing to their complicated compositions difficulties spatiotemporal coordination antigen-presenting cell activation antigen cross-presentation. Herein, a minimalist binary nanovaccine (BiVax) designed that integrates innate stimulating activity into carrier elicit robust antitumor immunity. The authors started by making series azole molecules end-capped polyethylenimine (PEI-M), were surprised find over 60% PEI-M polymers via stimulator interferon genes pathway. PEI-4BImi, obtained from polymers, elicits immune responses when used as subcutaneously injected simply mixing with ovalbumin antigens, this BiVax system performs much better than traditional ternary system, well as, commercialized aluminum-containing adjuvants. This also enables fast preparation personalized compositing PEI-4BImi autologous tumor membrane protein postoperative cure rate observed combined checkpoint inhibitors.

Language: Английский

Citations

84
An adjuvant strategy enabled by modulation of the physical properties of microbial ligands expands antigen immunogenicity DOI Creative Commons
Francesco Borriello, Valentina Poli, Ellen Shrock

et al.

Cell, Journal Year: 2022, Volume and Issue: 185(4), P. 614 - 629.e21

Published: Feb. 1, 2022

Language: Английский

Citations

81
Circular RNA vaccine induces potent T cell responses DOI Creative Commons
Laura Amaya, Lilit Grigoryan, Zhijian Li

et al.

Proceedings of the National Academy of Sciences, Journal Year: 2023, Volume and Issue: 120(20)

Published: May 8, 2023

Circular RNAs (circRNAs) are a class of commonly found across eukaryotes and viruses, characterized by their resistance to exonuclease-mediated degradation. Their superior stability compared linear RNAs, combined with previous work showing that engineered circRNAs serve as efficient protein translation templates, make circRNA promising candidate for RNA medicine. Here, we systematically examine the adjuvant activity, route administration, antigen-specific immunity vaccination in mice. Potent activity is associated uptake activation myeloid cells draining lymph nodes transient cytokine release. Immunization mice encoding antigen delivered charge-altering releasable transporter induced innate dendritic cells, robust CD8 T cell responses tissues, strong antitumor efficacy therapeutic cancer vaccine. These results highlight potential utility vaccines stimulating potent tissues.

Language: Английский

Citations

79
Understanding the Role and Impact of Poly (Ethylene Glycol) (PEG) on Nanoparticle Formulation: Implications for COVID-19 Vaccines DOI Creative Commons
Esperanza Padín-González,

Pearl Lancaster,

Massimo Bottini

et al.

Frontiers in Bioengineering and Biotechnology, Journal Year: 2022, Volume and Issue: 10

Published: June 7, 2022

Poly (ethylene glycol) (PEG) is a widely used polymer in variety of consumer products and medicine. PEGylation refers to the conjugation PEG drugs or nanoparticles increase circulation time reduce unwanted host responses. viewed as being well-tolerated, but previous studies have identified anti-PEG antibodies so-called pseudoallergic reactions certain individuals. The increased use contrast agents drug delivery, along with introduction mRNA vaccines encapsulated PEGylated lipid has brought this issue fore. Thus, while these proven be remarkably effective, rare cases anaphylaxis been reported, tentatively ascribed carriers, which may trigger complement activation susceptible Here, we provide general overview for pharmaceutical applications, discuss cascade that might caused by nanomedicines better understanding immunological adverse reactions.

Language: Английский

Citations

77